Aim­ing to jump ahead of Big Phar­ma heavy­weights, Seres moves to fi­nal­ize C. dif­fi­cile FDA pitch

C. dif­fi­cile pro­grams have flus­tered Big Phar­ma com­pa­nies and biotechs alike, but Seres is bar­rel­ing for­ward with its own mi­cro­bio­me treat­ment af­ter it says it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER